Publication | Closed Access
6576 POSTER Phase II Safety Study of the Oral Multikinase Inhibitor Regorafenib (BAY 73-4506) as Second-line Therapy in Patients With Hepatocellular Carcinoma
15
Citations
0
References
2011
Year
OncologyHepatologyBay 73-4506MedicinePathologyLiver CancerCancer TreatmentSecond-line TherapyPharmacologyRadiation OncologyHepatocellular Carcinoma
No additional data available for this publication yet. Check back later!